Connecticut Settled Generic Drug Price-Fixing Case
The state secured a $96 million settlement to compensate consumers who purchased specific generic drugs.
Updated on Sept. 22, 2026 in Healthcare
Live Poll
Do you trust that consumer price-fixing settlements provide fair compensation to affected individuals?
Connecticut has finalized a $96 million settlement with several major generic drug manufacturers to resolve allegations of market-wide price fixing. Eligible residents who purchased certain medications between 2009 and 2019 are now invited to file for compensation.
Why it matters
This settlement addresses claims that drug companies conspired to artificially inflate the costs of essential medications for public consumers. It serves as a financial recovery effort for those who paid higher prices during the decade-long period of alleged market rigging.
The settlement agreement total is $96 million, covering eligible generic medication purchases made across the state between 2009 and 2019. The list of drugs involved in the conspiracy allegations includes forms of albuterol, prednisone, and warfarin sodium.
The players
Attorney General's office
This state department is responsible for protecting the interests of Connecticut residents and is currently managing the claims distribution process.
Glenmark
This is a global pharmaceutical company named as one of the settling manufacturers in the price-fixing litigation.
Lannett
This manufacturer is a party to the settlement agreement following allegations of market-wide price manipulation.
Bausch
This pharmaceutical entity is included in the list of manufacturers that reached a settlement regarding generic drug pricing.
The details
The settlement involves six manufacturers: Glenmark, Lannett, Bausch, Apotex, Heritage, and Emcure. Connecticut residents who purchased the affected generic drugs during the specified window can file claims through an online portal or via a dedicated phone line facilitated by the Attorney General's office.
Timeline
The period for eligible generic medication purchases occurred from 2009 through 2019.
Market Landscape
This settlement follows the pattern set by prior national investigations into generic drug price-fixing by providing direct financial restitution to affected consumers. It reflects a broader trend of state-level legal action aimed at curbing anticompetitive practices within the pharmaceutical supply chain.
Residents who purchased generic medications such as albuterol, prednisone, or warfarin sodium during the 2009-2019 window may be entitled to financial compensation. Affected consumers should visit the official portal to review eligibility requirements and submit their claims.
The takeaway
Consumers who have long-term medical expenses for generic drugs should retain records of their purchases to ensure they can participate in future class action opportunities. Reviewing your medication history from the previous decade may uncover eligibility for this or similar state-led settlements.
Further reading
For broader developments on industry regulations, visit the Healthcare section.
More information
To file a claim, visit the generic drug settlement claim portal.
Live Poll
Do you trust that consumer price-fixing settlements provide fair compensation to affected individuals?
